Neurocrine Biosciences (NASDAQ:NBIX) Director Leslie Norwalk Sells 5,000 Shares

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Leslie Norwalk sold 5,000 shares of the business’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $152.23, for a total value of $761,150.00. Following the completion of the transaction, the director directly owned 7,429 shares of the company’s stock, valued at approximately $1,130,916.67. This trade represents a 40.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Neurocrine Biosciences Stock Down 4.7%

Shares of NBIX traded down $7.04 during trading hours on Wednesday, reaching $141.70. 1,740,144 shares of the company traded hands, compared to its average volume of 1,152,484. The stock has a market capitalization of $14.13 billion, a PE ratio of 33.90, a price-to-earnings-growth ratio of 1.01 and a beta of 0.27. The stock has a fifty day simple moving average of $145.88 and a 200 day simple moving average of $137.74. Neurocrine Biosciences, Inc. has a fifty-two week low of $84.23 and a fifty-two week high of $160.18.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Tuesday, October 28th. The company reported $2.17 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.59. The firm had revenue of $794.90 million during the quarter, compared to the consensus estimate of $746.61 million. Neurocrine Biosciences had a net margin of 15.95% and a return on equity of 15.82%. The firm’s revenue for the quarter was up 27.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.81 EPS. Research analysts predict that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. increased its stake in Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after acquiring an additional 135 shares during the last quarter. Golden State Wealth Management LLC lifted its stake in shares of Neurocrine Biosciences by 120.5% in the 3rd quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock valued at $26,000 after purchasing an additional 100 shares in the last quarter. Eastern Bank purchased a new stake in shares of Neurocrine Biosciences during the 3rd quarter worth about $27,000. WPG Advisers LLC purchased a new stake in shares of Neurocrine Biosciences during the 1st quarter worth about $32,000. Finally, Quent Capital LLC acquired a new stake in Neurocrine Biosciences during the 3rd quarter worth approximately $32,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on NBIX. HC Wainwright upped their price objective on shares of Neurocrine Biosciences from $168.00 to $198.00 and gave the company a “buy” rating in a research note on Wednesday. Weiss Ratings reiterated a “hold (c+)” rating on shares of Neurocrine Biosciences in a report on Wednesday, October 8th. UBS Group raised their price objective on Neurocrine Biosciences from $188.00 to $195.00 and gave the stock a “buy” rating in a report on Thursday, October 9th. Zacks Research raised Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 15th. Finally, JPMorgan Chase & Co. upped their target price on Neurocrine Biosciences from $171.00 to $179.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $174.76.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.